Valuation: Ipsen

Market Cap 11.75B 13.39B 11.1B 10.11B 18.93B 1,283B 19.07B 133B 51.43B 656B 50.27B 49.18B 2,107B P/E 2026 *
11.9x
P/E 2027 * 12.2x
Enterprise Value 10.41B 11.86B 9.83B 8.96B 16.77B 1,137B 16.89B 118B 45.57B 581B 44.54B 43.58B 1,867B EV / Sales 2026 *
2.28x
EV / Sales 2027 * 2.03x
Free-Float
40.65%
Yield 2026 *
1.07%
Yield 2027 * 1.07%
1 day+1.97%
1 week-3.17%
Current month-7.93%
1 month-8.83%
3 months-7.93%
6 months-0.07%
Current year+26.20%
1 week 146.5
Extreme 146.5
153.8
1 month 146.5
Extreme 146.5
169.1
Current year 116.5
Extreme 116.5
172.7
1 year 111.2
Extreme 111.2
172.7
3 years 90.2
Extreme 90.2
172.7
5 years 77.76
Extreme 77.76
172.7
10 years 36.84
Extreme 36.84
172.7
Manager TitleAgeSince
Chief Executive Officer 59 01/07/2020
Chief Executive Officer 57 01/01/2020
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 61 30/08/2005
Chairman 68 22/11/2010
Director/Board Member 69 01/06/2012
Change 5-day change 1-year change 3-year change Capi.($)
+1.97%-3.17% - - 13.9B
+0.13%+2.65%+65.61%+114.28% 1,053B
+0.20%+0.46%+52.60%+69.24% 652B
-0.29%+0.14%+20.96%+70.93% 468B
-0.85%+0.98%+41.29%+44.38% 351B
+0.71%+4.08%+22.24%+29.51% 273B
+1.23%+0.42%+14.57%+12.13% 254B
+2.11%+7.51%+52.89%+55.37% 220B
+0.83%+0.55%+35.99%+101.70% 186B
0.00%-10.14%-29.94%-60.30% 170B
Average +0.52%+0.60%+30.69%+48.58% 403.04B
Weighted average by Cap. +0.03%+1.19%+41.55%+67.89%

Financials

2026 *2027 *
Net sales 4.56B 5.2B 4.31B 3.93B 7.35B 498B 7.41B 51.58B 19.98B 255B 19.53B 19.1B 818B 4.65B 5.3B 4.39B 4.01B 7.5B 508B 7.55B 52.59B 20.37B 260B 19.91B 19.48B 835B
Net income 1.01B 1.15B 954M 870M 1.63B 110B 1.64B 11.42B 4.42B 56.39B 4.32B 4.23B 181B 982M 1.12B 927M 845M 1.58B 107B 1.59B 11.1B 4.3B 54.78B 4.2B 4.11B 176B
Net Debt -1.34B -1.53B -1.26B -1.15B -2.16B -146B -2.17B -15.13B -5.86B -74.69B -5.73B -5.6B -240B -2.3B -2.62B -2.17B -1.98B -3.7B -251B -3.73B -25.95B -10.05B -128B -9.82B -9.61B -412B
Logo Ipsen
Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows: - oncology (69.2%); - neuroscience (20.3%); - rare diseases (10.5%). At the end of 2025, the group had 7 research and development centers located in France (2), the United Kingdom (2), China (2) and Ireland, and 5 manufacturing sites worldwide. Net sales are distributed geographically as follows: France (8%), Europe (31.7%), the United States (32.9%), North America (2.2%) and other (25.2%).
Employees
5,535
Date Price Change
25/09/26 EUR 149.80 +1.97%
24/09/26 EUR 146.90 -1.74%
23/09/26 EUR 149.50 +1.15%
22/09/26 EUR 147.80 +0.89%
21/09/26 EUR 146.50 -5.30%
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
143.30EUR
Average target price
165.40EUR
Spread / Average Target
+15.42%

Quarterly revenue - Rate of surprise